Flaxel may be available in the countries listed below.
Ingredient matches for Flaxel
Celecoxib
Celecoxib is reported as an ingredient of Flaxel in the following countries:
- Peru
International Drug Name Search
Thursday 16 July 2009
Wednesday 15 July 2009
Lexiscan
Lexiscan is a brand name of regadenoson, approved by the FDA in the following formulation(s):
LEXISCAN (regadenoson - solution; intravenous)
Manufacturer: ASTELLAS
Approval date: April 10, 2008
Strength(s): 0.4MG/5ML (0.08MG/ML) [RLD]
Has a generic version of Lexiscan been approved?
No. There is currently no therapeutically equivalent version of Lexiscan available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lexiscan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
N-pyrazole A2A adenosine receptor agonists
Patent 6,403,567
Issued: June 11, 2002
Inventor(s): Jeff A.; Zablocki & Elfatih O.; Elzein & Venkata P.; Palle
Assignee(s): CV Therapeutics, Inc.
2-adenosine N-pyrazole compositions having the following formula: and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Patent expiration dates:
- April 10, 2022✓✓✓
- April 10, 2022
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
Patent 6,642,210
Issued: November 4, 2003
Inventor(s): Jeff A.; Zablocki & Elfatih O.; Elzein & Venkata P.; Palle
Assignee(s): CV Therapeutics, Inc.
N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.Patent expiration dates:
- June 22, 2019✓✓✓
- June 22, 2019
N-pyrazole A2A receptor agonists
Patent 7,144,872
Issued: December 5, 2006
Inventor(s): Zablocki; Jeff A. & Elzein; Elfatih O. & Palle; Venkata & Belardinelli; Luiz
Assignee(s): CV Therapeutics, Inc.
This specification discloses 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Patent expiration dates:
- June 22, 2019✓✓✓
- June 22, 2019✓✓✓
- June 22, 2019✓✓✓
- June 22, 2019
N-pyrazole A2A receptor agonists
Patent 7,183,264
Issued: February 27, 2007
Inventor(s): Zablocki; Jeff & Elzein; Elfatih O. & Palle; Venkata P. & Belardinelli; Luiz
Assignee(s): CV Therapeutics, Inc.
2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.Patent expiration dates:
- June 22, 2019✓✓
- June 22, 2019✓✓
- June 22, 2019✓✓
- June 22, 2019
Myocardial perfusion imaging method
Patent 7,582,617
Issued: September 1, 2009
Inventor(s): Belardinelli; Luiz & Blackburn; Brent K. & Gao; Zhenhai
Assignee(s): CV Therapeutics, Inc.
The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structure in myocardiological perfusion imaging.Patent expiration dates:
- June 22, 2019✓
- June 22, 2019
Use of A2A adenosine receptor agonists
Patent 7,655,636
Issued: February 2, 2010
Inventor(s): Gordi; Toufigh & Olmsted; Ann Walls & Lieu; Hsiao Dee & Belardinelli; Luiz
Assignee(s): Gilead Palo Alto, Inc.
The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, — an adenosine A2A receptor agonist — to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.Patent expiration dates:
- June 22, 2019✓
- June 22, 2019
N-pyrazole A2A receptor agonists
Patent 7,655,637
Issued: February 2, 2010
Inventor(s): Zablocki; Jeff A. & Elzein; Elfatih O. & Palle; Venkata & Belardinelli; Luiz
Assignee(s): Gilead Palo Alto, Inc.
2-adenosine N-pyrazole compounds having the following formula: wherein R1═CH2OH; R2 is hydrogen; R3 is selected from the group consisting of CO2R20; —CONR7R8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C 1-3alkyl and OR20;R4 is hydrogen; R7 is selected from hydrogen, and C1-3alkyl; R8 is hydrogen; and R20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.Patent expiration dates:
- June 22, 2019✓✓✓
- June 22, 2019
Myocardial perfusion imaging method
Patent 7,683,037
Issued: March 23, 2010
Inventor(s): Belardinelli; Luiz
Assignee(s): Gilead Palo Alto, Inc.
The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.Patent expiration dates:
- June 22, 2019✓
- June 22, 2019
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 10, 2013 - NEW CHEMICAL ENTITY
See also...
- Lexiscan Consumer Information (Drugs.com)
- Lexiscan Consumer Information (Cerner Multum)
- Lexiscan Advanced Consumer Information (Micromedex)
- Regadenoson Consumer Information (Cerner Multum)
- Regadenoson Intravenous Advanced Consumer Information (Micromedex)
Tuesday 14 July 2009
Exlutena
Exlutena may be available in the countries listed below.
Ingredient matches for Exlutena
Lynestrenol
Lynestrenol is reported as an ingredient of Exlutena in the following countries:
- Sweden
International Drug Name Search
Monday 6 July 2009
Dormid
Dormid may be available in the countries listed below.
Ingredient matches for Dormid
Midazolam
Midazolam is reported as an ingredient of Dormid in the following countries:
- Argentina
International Drug Name Search
Sunday 5 July 2009
Cefuroxim-MIP
Cefuroxim-MIP may be available in the countries listed below.
Ingredient matches for Cefuroxim-MIP
Cefuroxime
Cefuroxime is reported as an ingredient of Cefuroxim-MIP in the following countries:
- Poland
- Serbia
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Cefuroxim-MIP in the following countries:
- Bulgaria
International Drug Name Search
After Bite
After Bite may be available in the countries listed below.
Ingredient matches for After Bite
Ammonium Hydroxide
Ammonium Hydroxide is reported as an ingredient of After Bite in the following countries:
- Switzerland
International Drug Name Search
Subscribe to:
Posts (Atom)